UNSPSC 51123501: Ivabradine

This classification denotes an antiarrhythmic agent with the molecular formula C27H36N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3H48L0LPZQ, chemically known as 7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one but more generally known as ivabradine, which bears US NIH Compound Identifier 132999. European Medicines Agency schedules Ivabradine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08357MIG.

UNSPSC 51123501 Ivabradine, a Commodity code, encompasses prescription medications and related pharmaceutical products that state and local governments procure for emergency medical services, health agency programs, and cooperative purchasing vehicles. Recent solicitations show state and local buyers purchasing advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products through sealed bids, RFPs, and cooperative purchasing agreements. The issuing bodies include city fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances. Work under this code spans direct procurement of specific medication line items with defined unit quantities and expiration requirements, participation in state-administered cooperative purchasing frameworks, and exploration of direct-to-manufacturer prescription fulfillment models to reduce costs and improve supply chain efficiency.

Activity under the code appears in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted a sealed bid (IFB No. 26P00188) due April 8, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with four medication line items—Labetalol, Epinephrine, Adenosine, and Diltiazem—valued at approximately $40,000 with a one-year initial term and optional two-year renewals; the solicitation included a 5 percent Small Local Business Enterprise bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and other participating jurisdictions through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013, posted April 3, 2026) to explore vendor capabilities for direct-to-manufacturer prescription programs serving self-insured state and employee health plans outside traditional PBM channels, signaling potential future formal solicitation activity.